Compare PECO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PECO | DNTH |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.5B |
| IPO Year | 2010 | 2018 |
| Metric | PECO | DNTH |
|---|---|---|
| Price | $40.43 | $109.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $39.71 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 850.0K | 795.1K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 74.51 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $726,594,000.00 | $2,036,000.00 |
| Revenue This Year | $5.82 | N/A |
| Revenue Next Year | $3.81 | $29.48 |
| P/E Ratio | $71.68 | ★ N/A |
| Revenue Growth | ★ 9.86 | N/A |
| 52 Week Low | $32.98 | $19.84 |
| 52 Week High | $44.38 | $114.55 |
| Indicator | PECO | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 57.06 |
| Support Level | $40.18 | $79.27 |
| Resistance Level | $42.54 | $114.55 |
| Average True Range (ATR) | 0.80 | 5.58 |
| MACD | -0.32 | -0.21 |
| Stochastic Oscillator | 22.05 | 71.41 |
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.